Detail akcie Aldexa Therap online

Business Summary: Aldeyra Therapeutics, Inc. is a biotechnology company, which is engaged in discovering therapies designed to treat immune-mediated diseases. The Company's product candidates include reactive aldehyde species (RASP) modulators ADX-629, ADX-246, ADX-248, and chemically related molecules for the treatment of systemic and retinal immune-mediated diseases. Its pre-commercial product candidates are reproxalap, a RASP modulator for the potential treatment of dry eye disease and allergic conjunctivitis, and ADX-2191, a novel formulation of intravitreal methotrexate for the treatment of proliferative vitreoretinopathy and retinitis pigmentosa. Its ADX-629, is an orally administered RASP modulator in clinical development for atopic dermatitis, idiopathic nephrotic syndrome, moderate alcohol-associated hepatitis, chronic cough, and Sjogren-Larsson Syndrome. Its preclinical RASP platform includes ADX-246 and ADX-248 in development for metabolic, retinal diseases and systemic inflammatory diseases.
Financial Summary: BRIEF: For the fiscal year ended 31 December 2023, Aldeyra Therapeutics Inc revenues was not reported. Net loss decreased 39% to $37.5M. Lower net loss reflects Research and development decrease of 39% to $26.4M (expense), Interest income increase from $2.3M to $7.3M (income), General and administrative expenses decrease of 36% to $2.7M (expense). Basic Earnings per Share excluding Extraordinary Items increased from -$1.06 to -$0.64.